Tariffs and trade policymixed · 4 filings
“We expect that our gross margins will continue to be impacted by our launches in NSCLC and pancreatic cancer, as well as by the changing tariff landscape.”10-Q · Apr 30, 2026 ↗
NovoCure Limited
NVCR
Market read
NovoCure Limited's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Company+1.0% todayVolume comparison unavailable
Market group0 of 13 activeRegional Financial Services · unavailable
Disclosed network0 of 5 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- NVCR's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NVCR's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- NVCR's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations320
Usable filing statements75
Verified relationships4
Evidence supporting the case
- Latest annual revenue changed +8.3% year over year.
- Operating margin changed +4.7 percentage points in the latest annual period.
- Net margin changed +7.1 percentage points in the latest annual period.
Evidence challenging the case
- Diluted shares increased 3.4% in the latest annual period.
Questions before a position
- EV/sales is 60% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
15.496m+14.6%12m+28.8%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$535.0M+8.2%$-0.56-5.0%
2022-12-31$537.8M+0.5%$-0.88+1.2%
2023-12-31$509.3M-5.3%$-1.95+1.7%
2024-12-31$605.2M+18.8%$-1.56+1.4%
2025-12-31$655.4M+8.3%$-1.22+3.4%
What management says matters
Persistent and emerging business drivers
Legal and regulatory exposurenegative · 3 filings
“For the three months ended March 31, 2026, the change was primarily due to a $2.0 million increase in engineering costs mostly related to payroll increases, a $1.3 million increase in direct clinical expenses mostly related to the ramp up of our KEYNOTE D58 t…”10-Q · Apr 30, 2026 ↗
Supply chain and availabilitymixed · 3 filings
“For the three months ended March 31, 2026, the increase in cost of revenues was primarily due to 12% growth in active patients mostly offset by $4.2 million lower costs of arrays mainly resulting from improved array utilization and lower supplier prices.”10-Q · Apr 30, 2026 ↗
Foreign exchangenegative · 2 filings
“Financial income decreased $ 4.5 million or 43%, to $6.0 million for the three months ended September 30, 2025 from $10.5 million in income for the same period in 2024, primarily due to a $2.7 million decrease in interest income on our investments and an incr…”10-Q · Oct 30, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 2.6× · EV/sales 2.8×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
15.49+1.0% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for NVCR. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for NVCR. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind NVCR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
ZLABZai Lab LimitedpartnerAug 7, 2025 ▾
“Tumor Treating Fields (TTFields): In May 2025, our partner NovoCure presented results from the Phase III PANOVA-3 trial of TTFields therapy for pancreatic cancer at the 2025 ASCO Annual Meeting and simultaneously published in the Journal of Clinical Oncology.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NVCR is currently a Follower in the organic co-movement group Regional Financial Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for NVCR; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.